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Objectives: The financial basis of sick pay is provided by health insurance premi-
ums paid by employers and employees in Hungary. Due to the economic crisis in 
2007, the number of people employed significantly decreased. The aim of our study 
was to analyse the changes of nationwide sick-pay expenditures of the National 
Health Insurance Fund Administration of Hungary. MethOds: We used the data of 
National Health Insurance Fund Administration of Hungary and statistical reports 
of Nr. OSAP 1514, as well as data of Hungarian Central Statistical Office from the 
years of 2005-2013. We analysed the following indicators: average daily sick-pay 
expenditure and the nationwide sick-pay expenditures National Health Insurance 
Fund Administration, and the number of days spent on sick-leave. Results: In 
the investigated period the expenditure for one day of sick-pay gradually increased 
between the years of 2005 and 2009, from 2420 to 3101 Hungarian Forint (HUF). This 
is closely correlated with the changes of the average general wages. The general 
daily amount of sick-pay between 2010-2012 stagnated on 2700 HUF, then increased 
to 2929 HUF in 2013. Sick-pay expenditure of the National Health Insurance Fund 
Administration was around 100 billion HUF between 2005-2008, in 2009 it reached 
108 billion HUF. Tthen due to governmental actions after the economic crisis it fell 
by 26% in 2010 (79 billion HUF), with further decline to 57 billion HUF in 2012 and 60 
in 2013. In the investigated period the number of days spent on sick-leave decreased 
from 37.4 million to 19.8 million. cOnclusiOns: We can conclude that the amount 
spent on sick-pay paid by the National Health Insurance Fund in Hungary between 
2005 and 2013 significantly decreased. Thus the sick-pay expenditures were strongly 
influenced by the economic crisis.
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Objectives: High rates of preterm birth and limited access to evidence-based, 
cost-effective interventions unsupported by fragmented and unsystematic financ-
ing hinder child mortality reduction locally. We aimed to cost a full spectrum of 
care for prematurity complications, to develop a comprehensive benefit pack-
age to ensure financial risk protection through the National Health Insurance 
Program. MethOds: Two frameworks of standard care algorithms and outcomes 
were developed in two birthweight categories (500-< 1,500g; 1500-< 2500g) and for 
women at < 37 weeks using literature- and expert-panel-based data. Valuation of 
cost components was done. Gross costing was used for accommodation-related 
costs, where general service components were aggregated; modified microcosting 
for clinical-related costs, with patient and hospital specific costs identified; and 
modified bottom-up approach for patient-specific unit costs per service. Component 
costs from 11 hospitals and 3 maternity clinics surveyed nationwide were entered 
into a configured spreadsheet. Results: 17 Diagnosis-Related Groups (DRGs) were 
formed, subdivided into antenatal (e.g., antenatal steroids, maternal transfer), inpa-
tient (e.g. NICU, Kangaroo Mother Care) and pre-discharge care (e.g. screening, vac-
cinations, counseling), with calculated unit costs and DRG weights for each. The 
lowest cost inpatient package was for the birthweight 1500 - 2499g with minor 
complications subgroup - approximately 32.4% of all preterms. The highest cost 
was for ~5.1% of all preterms, birthweight 500 - < 1500g requiring intensive care 
for major complications then Kangaroo Mother Care. cOnclusiOns: Algorithms 
of standard care and outcomes for two birthweight categories and itemized cost 
modeling were used for prospective evaluation of costs. Results of the costing exer-
cise of 17 DRGs will inform actuarial analyses, for final decision on the eventual 
package design spanning primary to “catastrophic” care for premature newborns. 
disclosure of Financial support This technical assistance project for the Philippine 
Health Insurance Corporation was supported by UNICEF Philippines. Any opinion 
stated are the authors’ and not of UNICEF.
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Objectives: To develop a method of setting a Drug Price Reference Index (DPRI) 
in the Philippines to ensure good value for money in the procurement and reim-
bursement of essential medicines. MethOds: A database of prevailing drug pro-
curement prices was created from actual purchase orders submitted in 2013 by 
government procuring entities in the Philippines. The database includes informa-
tion on the unit cost, volumes of procurement, source/supplier/manufacturer, 
brand, mode of procurement and location of the hospital for each formulation 
and strength of all drugs in the National Formulary. Multivariate regression analy-
ses were performed for commonly sourced essential drugs exploring possible 
determinants of drug costs, which include quantities procured and hospital bed 
capacity. Further cost-comparisons were made for other potential determinants 
such as mode of procurement, supplier/manufacturer and distance of distribu-
tion. Results: Price data was analyzed for 20 drug products with the highest 
share of procurement in terms of volume and value. Extreme wide variations 
in unit costs were consistently observed for all drugs analyzed. The price dif-
ferentials, i.e. high/low ratio, was found to be up to 60 times when comparing 
the highest to the lowest priced drugs. The variations in prices were not associ-
ated by volumes procured, distance of distribution and hospital bed capacity. 
Objectives: Pharmaceutical companies have been able to submit information 
related to pharmacoeconomics as a reference material when applying for National 
Health Insurance drug price listing under current Japanese system. The purpose of 
this study is to investigate a role of pharmacoeconomic analysis in achieving high 
drug pricing in the past. MethOds: The status of acquiring premium for drugs 
listed on drug price listing in 10 years from 2004 to 2013 in Japan was studied. 
For drugs acquired premium for usefulness I and premium for innovation with 
further premium expected, papers studied on cost-effectiveness of the drug for 
Japanese patients were searched by Pubmed and Japan Medical Abstracts Society 
database, to investigate the role of pharmacoeconomic analysis in assessing pre-
mium acquisition. Results: There were 9 new drugs which acquired premium 
for usefulness I in 10 years from 2004 to 2013 in Japan. No new drug was granted 
premium for innovation. There were cost-effectiveness studies having the same 
indication on 2 drugs, one each for the drugs (Cinacalcet hydrochloride for second-
ary hyperparathyroidism under maintenance dialysis: premium rate 25% [2007], 
Perflubutane for imaging of hepatic mass lesions in ultrasonography: premium rate 
35% [2006]). No relationship for considering premium rate was observed from each 
paper. cOnclusiOns: Although pharmaceutical companies have been allowed to 
submit pharmacoeconomicanalysis when applying for drug price listing of new drug 
in Japan, it may have not been fully functioned. Pharmaceutical companies would 
have a meaningful discussion on consideration for pharmacoeconomic analysis 
utilization, heading towards introduction of pharmacoeconomic analysis on a trial 
basis starting from the 2016 fiscal year.
PHP113
external and internal referenCe PriCing as COst COntainment 
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Objectives: The prices of medicinal products paid by public funds in Bulgaria 
are regulated according to the legislation on the basis of the lowest manufacturer 
price of the same product in seventeen European countries. The Positive Drug List 
includes medicinal products which are paid by the National Health Insurance Fund 
(NHIF), medicinal products paid from the budget of the hospitals and medicinal 
products for treatment of AIDS, infectious diseases, as well as vaccines, specific 
sera, immunoglobulins, paid by the Ministry of health (MH). The goal of the study 
is to determine the influence of external and internal reference pricing as a cost 
containment measure for one year period. MethOds: The analysis is made on a 
basis of cost for medicinal products paid by NHIF, MH and hospitals based on the 
reference value of each INN during 2014. We analyzed the changes in reference 
value of INNs. Only the official prices are used, i.e. we did not take into account 
the confidential discounts. Results: In PDL medicinal products are grouped by 
INN and pharmaceutical form and the reference value within the group is set 
on a basis of the cheapest product. The prices of medicinal products included 
in PDL are checked every 6/12 months. For medicines paid by NHIF, the refer-
ence value of 85 INNs is reduced, the reduction ranges from 0.14% to 55.27% and 
total savings are 10,319,703 BGN. 31 INNs in oncology medicines for hospital use 
have reduced reference value and total savings are 9,852,593 BGN. For medicinal 
products paid by MH, 10 INNs have reduced reference value and total savings 
are 2,077,892 BGN. cOnclusiOns: Analysis of changes in the reference values 
of medicinal products indicates that external and internal reference pricing is a 
good basis for saving public funds, but other cost containment measures are also 
needed.
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Objectives: Rejection of kidney transplants remains a challenging clinical problem. 
Traditional immunosuppression (IS) consisting of CNI and other drugs effectively 
prevent rejection but are nephro-toxic and favor the development of malignancies 
and cardiovascular events and therefore compromise patient outcomes. Biomarker-
driven immunosuppression is an approach currently studied to identify patients 
eligible for reduced IS based on assessing the anti-donor alloimmune response. 
Our objective is to present the health-economic study design incorporated in the 
CELLIMIN study to investigate the impact of a biomarker-stratification panel to 
identify patients eligible for reduced IS. MethOds: CELLIMIN is a prospective rand-
omized controlled clinical trial that will randomize 301 patients, eligible for reduced 
IS, on a 1:1 ratio to a “high-IS” and a “low-IS” regime. Comparisons will be made 
between these arms and assumed full IS regimes. In addition to clinical outcomes, 
health economic outcomes will be collected following transplantation. Costs for 
IS medication are likely to decrease. A reduction in adverse events attributable 
to IS might further reduce costs. Additional costs for the stratification process, 
as well as for additional monitoring visits to precisely control blood trough lev-
els of IS medication might increase total costs. Results: Resource consumption 
is assessed alongside the CELLIMIN trial at initial discharge, repeated discharge, 
M12, and M24. We developed health-economic questionnaires for the initial hospi-
talization, repeated hospitalizations and for regular study visits to capture in- and 
outpatient resource consumption. Quality of life will be assessed using disease-
specific (KTQ) and generic questionnaires (SF-36v2 and EQ5D-5L). EQ5D-5L values, 
along with mortality data, will be used to compute quality adjusted life years that 
will inform incremental cost-effectiveness analyses. cOnclusiOns:: Prospective 
inclusion of health-economic endpoints in clinical trials is important to support 
future decision-making by payers and providers. The CELLIMIN study collects tar-
geted information on quality of life and resource utilization to facilitate future 
health-economic analyses.
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671). The mean annual overall direct health care cost for using lactate-based bal-
anced solution was estimated to be 2.16 billion rubles ($40.3 million), and for using 
acetate-based balanced solution - 2.05 billion rubles ($38.3 million). The CMA has 
shown that annual savings when used as a balanced infusion therapy acetate-based 
solution will be 110 million rubles ($ 2.05 million). cOnclusiOns: The using for 
infusion therapy acetate-based balanced solution Jonosteril® was more economi-
cally justified treatment option.
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PenetratiOn Of BiOsimilars intO tHe turkisH PHarmaCeutiCal market
Tuna E1, Kockaya G2
1Hacettepe University, Ankara, Turkey, 2Health Economics and Policy Association, Ankara, Turkey
Objectives: Despite concerns about interchangeability and substitution of bio-
similar products with reference products, they provide cost savings either by 
leading price reductions or increase in discounts of reference products. There 
are several studies demonstrating the actual/potential cost saving effects of bio-
similars. In this regard, the aim of this study is to define the price reductions 
or increase in discounts of reference products by the reimbursement of their 
biosimilars in Turkey. MethOds: Biotechnology products, which are still avail-
able in the market, are selected from the list of pharmaceutical products pub-
lished on the Ministry of Health’s web site. Their registration dates and ex-factory 
prices and statuary discounts between 2009 and 2014 are searched. Afterwards, 
the change in the reference products’ ex-factory prices and statuary discounts 
is analyzed for the first year that biosimilar products are reimbursed. Results: 
Not considering the different forms of drugs there are 80 biotechnology products 
(66 active ingredients) being marketed in Turkish pharmaceutical market. 10 of 
them are biosimilar products (7 active ingredient). The first biotechnology product 
and the biosimilar product were registered in Turkey in 1992 and 2009 respec-
tively. Only 4 active ingredients have both biosimilar and the reference product. 
By the reimbursement of the biosimilar products, the statuary discount of all 
the reference products increased between %14 and %113 and the price of the 2 
reference product decreased by %26 and %31 while the prices of other products 
didn’t change. cOnclusiOns: Depending on the analysis bio-similars may have 
a cost-reduction impact on pharmaceutical budgets. Further analysis should be 
conducted on the reason of price reductions of reference products by penetration 
of biosimilars whether by leading direct reductions or increased discounts in order 
to exempt the effect or general pricing regulations or cost containment measures 
unlikely to be specific to biotechnology products.
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defining value wHen launCHing BiOsimilars treatments witHin 
eurOPean HealtHCare systems
White R, Staples O
ZS Associates, London, UK
Objectives: To understand how EU healthcare decision makers define value when 
assessing biosimilar treatments MethOds: Combination of desk research to track 
current biosimilar market trends, followed by qualitative research including one-to-
one interviews with six EU sub-national payers and key opinion leaders. Results: 
European payers consider more than just list and net prices when purchasing and 
supplying novel biosimilar treatments for patients. Whilst payers do consider key 
aspects such as product attributes in the decision making process, it is economic 
and public health benefits, supply chain quality, reputation of the manufacturer, 
national guidance, support and demand from key units or physicians within their 
region, that remain as the most influential factors in the decision making pro-
cess. cOnclusiOns: Many EU payers still consider value beyond just price of a new 
medicine. However, recent biosimilar launches in the Nordics are challenging this 
paradigm and affecting discount expectations on biosimilars vs. original compounds 
in western EU countries. While sub-national payers need to ensure that biosimilar 
medicines can be supplied to their patients at a consistent level of quality and quan-
tity, biosimilar manufacturers need to ensure new compounds are launched into 
the market, at suitable price, with a successful commercial strategy that includes 
dedicated sales and marketing efforts. Moving forward, it will be important for bio-
similar manufacturers to understand what payers, physicians and patients value 
within a new medicine before entering price discussions.
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Objectives: In Brazil, law regulates the use of human albumin and divide recom-
mendations into formal, questionable and unsubstantiated. The aim was to verify 
compliance with the requirements of this medicine in relation to national guidelines 
and calculate the costs of unsubstantiated indications of human albumin 20%, 
at a public hospital. MethOds: We evaluated the records of patients who used 
human albumin 20% during hospitalization at a public hospital in the period from 
August, 2013 to August, 2014. There were no restrictions as patient age or duration of 
therapy. Quantitative variables were expressed as by mean and standard deviation, 
and not quantitative variables in by absolute and relative frequency. Results: We 
evaluated the records of 63 patients with a mean age of 60.6 ± 71.8 years. Most of 
them were men (40; 64.5%). Length of stay was 30.0 ± 47.2 days. Duration of albu-
min therapy was 6.0 ± 6.7 days (mean). Average total cost was US $ 174.13 ± 195.10 
per patient. Nineteen (30.2%) of albumin indication was classified as questionable 
and 15 (23.8%) as unsubstantiated. Cost of unsubstantiated indications was US $ 
2,379.80/year or US $ 158.65/patient, this represents 21.7% costs of albumin during 
the study period. Unsubstantiated indications were: use in intensive care (12; 19.0%), 
fluid replacement in acute losses (2; 3.2%) and hypoalbuminemia in patients with 
Suppliers were also observed to charge different prices for the same brands to 
different public hospitals, indicating information asymmetry on reasonable prices 
of drugs. cOnclusiOns: Based on the observed wide variations in drug procure-
ment prices in the Philippines, setting the DPRI at the median value for most 
drugs was found to be an appropriate method to set ceiling prices for public sector 
procurement. For monopolized pharmaceutical products, other methods may be 
more appropriate such as value-based pricing, price negotiations and external 
reference pricing to relevant countries.
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Jósa andrás HOsPital COmPlex PrOJeCt - COst-Benefit analysis Of tHe 
maJOr PrOJeCt investment
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Objectives: To work out the cost-benefit analysis (CBA) of the infrastructural devel-
opment major project of Jósa András Teaching Hospital (Nyíregyháza, Hungary) 
funded by EU grants. Two supported projects (complex hospital development and 
an integratedemergency care unit) were merged and had to be revised according 
to the major project requirements because of the recent significant cost increases. 
At the end of 2014 the project in value of 56.15 million EUR was submitted to the 
European Commission. MethOds: The CBA was based on the guidelines outlined 
in the EU Regional Policy and concerning Working Document. A 25-year time horizon 
was determined . 5% financial and 5.5% social discount rate were applied, as recom-
mended in the guidelines. Analyses were conducted using the incremental method 
considering Business as usual and Project scenario. To express the monetary value 
of socio-economic benefits we applied the willingness-to-pay method. The value of 
24,772 EUR was used as an average value of human life year based on the published 
data (EuroVaq) regarding the Hungarian population. Aggregating socio-economic 
benefits, we considered the monetized values of the following health gains: reduc-
tion in the 30-day AMI death rate, in county cancer deaths, in infant mortality, in 
the number of registered people with permanent disabilities, in lost income and 
health gain attainable through improving the quality of care. Results: Financial 
net present value (-50.6 million EUR), economic net present value (27.3 million EUR), 
financial rate of return (-8.15%), economic rate of return (9.44%) and cost-benefit 
ratio (1.62) were calculated as results of CBA. cOnclusiOns: The CBA reflected the 
fact that health care investments in the public sector are not directly financially 
recovered for the owner, but - considering the broader socio-economic effects - the 
project meets the requirement that the level of socio-economic benefits are higher 
than the socio-economic costs.
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HOw imPOrtant is tHe time faCtOr? saving lives using fire and 
resCue serviCes
Jaldell H
Karlstad University, Karlstad, Sweden
Objectives: The shorter the response time of emergency services the more lives are 
saved. But, how important in fact is the time factor for saving lives? The objective of 
this study is to analyse the relation between response time and fatalities, to be able 
to measure how many lives could be saved with a shorter response time. MethOds: 
The study uses data from reports from the fire and rescue services in Sweden for 
2005–2013 for residential fires. The time variable used is continuous and the sta-
tistical methods are non-linear regression techniques. Results: It is found that 
the risk of fatality is a non-linear function of response time. The marginal effect 
of response time is first large, then decreases, and eventually seems to approach 
zero. If it was possible to decrease the median response time by one minute 0.00035 
lives could be saved for every turn-out. For all turn-outs to residential homes that 
means that about two lives, or 3%, could be saved per year. The response time 
is most important for blocks of flats, nursing homes and semi-detached/terraced 
houses. The response time is more important for fires due to smoking, children 
playing or started intentionally (arson). cOnclusiOns: The results can be used to 
evaluate the performance of local fire and rescue services. It can also be used as a 
planning tool for fire and rescue services when it comes to the importance of dif-
ferent causes of injuries. The method is easy to use for other emergency services, 
such as ambulances.
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Objectives: The main aim of this study was to conduct a comparative phar-
macoeconomic analysis of the using 2 variants of balanced crystalloids infusion 
therapy – acetate- (Jonosteril®) and lactate-based (Sterofundin ISO®). MethOds: 
Analysis of the published clinical trials was conducted to evaluate comparative 
efficacy and safety of using balanced solutions of different composition. Direct 
medical costs for using 2 variants of balanced infusion therapy were calculated. 
Taking into account the hypothesis of equal effectiveness of balanced solutions of 
different compositions for pharmacoeconomic analysis was chosen “cost minimi-
zation” analysis (CMA). To calculate the direct costs of infusion therapy was deter-
mined the average duration of infusion therapy in patients with traumatic shock 
conditions in the intensive care unit on the basis of the actual practice of the N.V. 
Sklifosovsky Research Institute of Emergency Care. Direct costs were included the 
cost of one day of application infusion therapy on the basis of 2000 ml per day for 1 
patient. Results: According to published trials the using of different combinations 
of crystalloids such as acetate- and lactate-based were provided equal hemody-
namic stability. The average cost of a course of infusion therapy in patients with 
traumatic shock conditions by using acetate-balanced based solution was 34 104 
rubles ($ 636.8), and by using lactate- based balanced solution - 35 936.8 rubles ($ 
